ARROW

NCT03037385 📎

Regimen

Experimental
pralsetinib
Control
none

Population

RET fusion+ NSCLC

Key finding

Pretreated ORR 61% (50-71); tx-naive ORR 70%; another RET-selective TKI

Source: PMID 34118197

Timeline

  • Enrollment start: 2017-03-17 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.105)
  • CSCO NSCLC 2025 ⚠️ OCR source